Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada; Department of Medicine, Faculty of Medicine, Division of Palliative Care, UBC, Vancouver, BC, Canada; Faculty of Pharmaceutical Sciences, UBC, Vancouver, BC, Canada.
Department of Psychology, Queen's University, Kingston, ON, Canada.
Eur J Intern Med. 2021 Jul;89:10-18. doi: 10.1016/j.ejim.2021.05.002. Epub 2021 May 31.
Medical cannabis use is increasing worldwide. Clinicians are commonly asked by patients to provide guidance on its safety and efficacy. Although there has been an increase in research on the role of medical cannabis for a number of different conditions, we found that there was a paucity of clear safety guidance on its use. We aim to address this issue by answering two pertinent clinician safety questions: 1 Can medical cannabis be safely used in this patient? 2. What strategies can be used to ensure that any harms from medical cannabis are mitigated? To address these questions, we reviewed available evidence and provided expert clinical opinion to summarize the fundamental components for evaluating medical cannabis safety and strategies to reduce risk from its use. Our review resulted in a safety-focused framework for medical cannabis initiation and utilization. We provide clear recommendations for patients being considered for cannabis (e.g. precautions, contraindications and drug interactions). Risk mitigation strategies such as appropriate chemovar (strain) selection, routes of administration, and dosing are reviewed. As with any other pharmacotherapy, we review the key components of monitoring and address potential issues that may arise while using medical cannabis. We propose a structured assessment and monitoring strategy that can be used by clinicians recommending cannabis (CRC) to guide patients through each step of their cannabis journey. This framework can be used to ensure that medical cannabis utilization is associated with the lowest possible risk to the patient.
医用大麻的使用在全球范围内呈上升趋势。患者经常向临床医生寻求关于其安全性和疗效的指导。尽管对医用大麻在许多不同疾病中的作用的研究有所增加,但我们发现,关于其使用的安全性的明确指导却很少。我们旨在通过回答两个相关的临床医生安全性问题来解决这个问题:1. 对于该患者,医用大麻能否安全使用?2. 可以采用哪些策略来确保减轻医用大麻的任何危害?为了解决这些问题,我们回顾了现有证据并提供了专家临床意见,以总结评估医用大麻安全性的基本要素和减轻其使用风险的策略。我们的综述得出了一个以安全性为重点的医用大麻起始和使用框架。我们为正在考虑使用大麻的患者提供了明确的建议(例如注意事项、禁忌证和药物相互作用)。我们还回顾了风险缓解策略,例如适当的化学变种(品种)选择、给药途径和剂量。与任何其他药物治疗一样,我们审查了监测的关键组成部分,并解决了在使用医用大麻时可能出现的潜在问题。我们提出了一个结构化的评估和监测策略,可由推荐大麻的临床医生(CRC)用于指导患者完成大麻使用的每个步骤。该框架可确保医用大麻的使用给患者带来的风险最小化。